- Trials with a EudraCT protocol (157)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
157 result(s) found for: CD4 antigen.
Displaying page 1 of 8.
EudraCT Number: 2023-000061-14 | Sponsor Protocol Number: BCN04-DASA | Start Date*: 2023-05-26 | |||||||||||
Sponsor Name:Institut de Recerca Germans Trias i Pujol | |||||||||||||
Full Title: Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People with HIV under Antiretroviral Treatment | |||||||||||||
Medical condition: Human immunodeficiency virus (HIV) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002633-39 | Sponsor Protocol Number: SHCS-Projekt Nr. 408 | Start Date*: 2005-02-17 |
Sponsor Name:Prof. Dr. med. Milos Opravil, Universitätsspital Zürich | ||
Full Title: Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance (a multicenter prospective clinical study within the SH... | ||
Medical condition: HIV patients with virological treatment failure due to multi-drug-resistant virus including 3TC resistance | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000445-12 | Sponsor Protocol Number: IPAR0001 | Start Date*: 2012-07-17 | |||||||||||
Sponsor Name:Department off Infectious Diseases, Aarhus University Hospital Skejby, Denmark | |||||||||||||
Full Title: Immune Response to Bivalent or Quadrivalent Human Papilloma Virus vaccination in Patients with Chronic Renal Failure | |||||||||||||
Medical condition: Cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004863-69 | Sponsor Protocol Number: 108494, 108516, 108518, 108520 | Start Date*: 2006-12-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of... | ||
Medical condition: Primary immunization of healthy elderly subjects (60 to 69 and more than or equal to 70 years) against zoster | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SE (Completed) CZ (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001815-21 | Sponsor Protocol Number: 212340 | Start Date*: 2019-10-23 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIB, open label, long term follow-up study to assess persistence of immune responses to GSK’s HZ/su vaccine 4-7 years after primary vaccination; and immunogenicity and safety assessment of... | ||
Medical condition: Herpes Zoster | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001490-95 | Sponsor Protocol Number: ESPRIT 002: STALWART | Start Date*: 2006-04-21 |
Sponsor Name:National Institute of Allergy and Infectious Diseases (NIAID) | ||
Full Title: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022293-14 | Sponsor Protocol Number: ANRS146OPTIMAL | Start Date*: 2012-08-22 |
Sponsor Name:Inserm-ANRS | ||
Full Title: Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017141-58 | Sponsor Protocol Number: V111_06TP_OPERA | Start Date*: 2009-11-19 | |||||||||||
Sponsor Name:OPERA SRL | |||||||||||||
Full Title: An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovale... | |||||||||||||
Medical condition: Prophylaxis of A/H1N1sw influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022248-19 | Sponsor Protocol Number: 114825 | Start Date*: 2011-01-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... | |||||||||||||
Medical condition: Evaluation of persistence of immune responses following immunisation of healthy elderly subjects (60-69 and ≥70 years) against Herpes Zoster (HZ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) NL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023791-63 | Sponsor Protocol Number: V70_34 | Start Date*: 2011-03-24 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | |||||||||||||
Full Title: A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unva... | |||||||||||||
Medical condition: influenza | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2024-000422-17 | Sponsor Protocol Number: C3671016 | Start Date*: 2024-08-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 1, OPEN-LABEL, AGE DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN ... | |||||||||||||
Medical condition: Prevention of RSV-associated lower respiratory tract illness in children 2-18 years of age by active immunization | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005466-34 | Sponsor Protocol Number: HPVAIN1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men | |||||||||||||
Medical condition: HPV16-induced intra-anal high-grade AIN (grade 2-3) in HIV+ men, that was resistant to, or recurred after conventional cauterization or other forms of local treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002541-37 | Sponsor Protocol Number: 116777 | Start Date*: 2012-08-14 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase II, open label, mono-centric study to evaluate the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 in healthy BCG-primed, HIV-... | ||
Medical condition: Healthy volunteers (Prevention of tuberculosis [TB] disease in children, adolescents and adults) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002112-16 | Sponsor Protocol Number: STH17302 | Start Date*: 2014-09-15 |
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||
Full Title: Analysis of the immune response to Fendrix as compared to double-dose Engerix B in HIV-infected non-responders to standard Hepatitis B vaccination courses | ||
Medical condition: Vaccine responses to hepatitis B vaccinations in HIV-infected individuals who do not respond to standard vaccination courses | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001820-36 | Sponsor Protocol Number: 114886 | Start Date*: 2012-10-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine GSK 692342 when administered to ... | |||||||||||||
Medical condition: Vaccination against tuberculosis (TB) in adults aged 18 to 59 years with TB disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001727-12 | Sponsor Protocol Number: TPV11 | Start Date*: 2019-10-24 | |||||||||||
Sponsor Name:Topas Therapeutics GmbH | |||||||||||||
Full Title: A multi-centre, open-label, phase 1 study, Part A single ascending dose and Part B multiple dose, to evaluate the safety, tolerability and pharmacokinetics, and to explore early signs of effectiven... | |||||||||||||
Medical condition: Pemphigus vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002129-31 | Sponsor Protocol Number: 19IC5249 | Start Date*: 2019-12-12 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: The RIO Trial: A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral ... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004400-30 | Sponsor Protocol Number: 204926 | Start Date*: 2016-02-24 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IIIB, open, long term extension study to evaluate the persistence of immune responses and the safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A, at Months 108 and 12... | ||||||||||||||||||||||||||||
Medical condition: Herpes Zoster (HZ) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Completed) DE (Completed) CZ (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005059-18 | Sponsor Protocol Number: 116886 | Start Date*: 2013-05-24 | |||||||||||
Sponsor Name:GlaxoSmithKline S.A. | |||||||||||||
Full Title: A Phase III, randomised, observer-blind, placebo-controlled, multicentre clinical study to assess the immunogenicity and safety of GSK Biologicals? HZ/su candidate vaccine when administered intramu... | |||||||||||||
Medical condition: Herpes Zoster (HZ) and its related complications | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) BE (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002360-28 | Sponsor Protocol Number: 104886 | Start Date*: 2005-09-13 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: An open, randomized phase I/II study to demonstrate the non inferiority in term of cellular mediated immune response between GlaxoSmithKline Biologicals influenza candidate vaccines containing vari... | ||
Medical condition: Immunisation against influenza disease in adults aged 18-40 years and elderly population aged over 65 years (>65 years) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
